ViroMed Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
266
159
257
714
6,496
Depreciation, Depletion & Amortization
571
560
539
401
462
Other Funds
507
599
1,185
740
560
Funds from Operations
1,343
1,318
1,981
1,053
5,474
Changes in Working Capital
1,091
914
770
1,332
3,971
Net Operating Cash Flow
252
404
1,211
2,385
1,503
Capital Expenditures
8,069
6,977
9,889
21,317
35,677
Sale of Fixed Assets & Businesses
20
154
-
2
4
Purchase/Sale of Investments
4,193
809
2,769
33,181
6,106
Net Investing Cash Flow
1,331
2,026
844
149,465
5,142
Issuance/Reduction of Debt, Net
250
236
87
3,792
6,791
Net Financing Cash Flow
2,526
236
87
156,604
6,791
Net Change in Cash
1,376
1,313
284
4,961
9,179
Free Cash Flow
97
258
1,011
9,965
10,075
Other Sources
7,148
16,987
8,482
5,601
140,121
Change in Capital Stock
2,277
-
-
152,812
-
Exchange Rate Effect
72
73
3
207
1,251
Other Uses
4,623
12,999
2,206
100,570
105,411

About ViroMed Co.

View Profile
Address
203 Bldg. Natural Science College
Seoul SL 08733
Korea, Republic Of
Employees -
Website http://www.viromed.co.kr
Updated 09/14/2018
ViroMed Co., Ltd. engages in the development and manufacture of biopharmaceuticals for human diseases. It operates through the Natural Materials and Biomedical Products Business Divisions. Its products include technologies for diseases.